Updates are available Correction dated 2022-01-25

Article History

Received: 29 March 2021

Accepted: 20 July 2021

First Online: 24 August 2021

Change Date: 25 January 2022

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s12072-022-10301-2

Conflict of Interest

: Ming-Lung Yu received research grants from Abbott, BMS, Gilead and Merck and received fees for being a speaker/consultant from Abbvie, Abbott, BMS, Gilead, Merck, Ipsen and Roche. Grace Wong has served as an advisory committee member for Gilead Sciences and Janssen, as a speaker for Abbott, Abbvie, Bristol-Myers Squibb, Echosens, Furui, Gilead Sciences, Janssen and Roche, and received research grant from Gilead Sciences. Alexander Thompson has served as an advisory committee member for Gilead Sciences, Abbvie, Roche, BMS, Merck, Immunocore, Janssen, Assembly Biosciences, Arbutus, Eisai, Ipsen and Bayer, as a speaker for Gilead Sciences, Abbvie, Roche, BMS, and received research grant from Gilead Sciences, Merck, BMS, Abbvie. Jin-Lin Hou received grants and personal fees from Bristol-Myers Squibb during the conduct of the study, and grants and personal fees from Bristol-Myers Squibb, GlaxoSmithKline, and Novartis. Teerha Piratvisuth received fees for being a speaker and advisory board member from Bayer, BMS, Gilead Sciences, and Eisai and received research support from Fibrogen, Gilead Sciences, Janssen and Roche. Ji-Dong Jia received consultation and speaker fees from Bristol-Myers Squibb, Gilead, Merck Sharp and Dohme, Novartis, and Roche. Ann-Lii Cheng received consultant fees from Novartis, Merck Serono, Eisai, Merck Sharp and Dohme, ONXEO, Bayer, Bristol-Myers Squibb, and Ono Pharmaceutical. Tony Mok received fees for being a speaker, consultant, and advisory board member from AstraZeneca, Roche/Genentech, Lilly, Bristol Myers Squibb, Boehringer Ingelheim, Novartis, Merck Sharp & Dohme, Pfizer, Merck Serono, SFJ Pharmaceuticals Group, ACEA Biosciences, Vertex, Celgene, Ignyta, Fishawack Facilitate Ltd, Takeda, Janssen, Hutchison MediPharma, and received grants from AstraZeneca, Boehringer Ingelheim, Pfizer, Novartis, SFJ Pharmaceuticals Group, Roche, Merck Sharp & Dohme, Clovis Oncology, Bristol Myers Squibb, Xcovery. Diana A. Payawal has served as an advisory committee member for Mylan Pharmaceutical, as a speaker for Gilead Sciences, Mylan Pharmaceuticals, Echosense, Getz and Abbott. Tawesak Tanwandee received grants from Bristol-Myers Squibb and Merck. Masao Omata received fees for being a speaker, consultant, and advisory board member from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Otsuka, Astellas, Gilead Sciences, Chugai, Mitsubishi Tanabe, Kyorin, Merck Sharp and Dohme, Dainippon Sumitomo, Vertex Pharmaceuticals, Takeda, Merck Serono, and Zeria. George Lau, Hasmik Ghazinian, Masashi Mizokami, Gregory Cheng, Guo-Feng Chen, Zhen-Wen Liu, Oidov Baatarkhuu, Woon Leung Ng, Patrick Lau, Jer-Ming Chang, Saeed Hamid, A. Kadir Dokmeci, Rino A Gani, Diana A. Payawal, Pierce Chow, Joong-Won Park, Simone I Strasser, Rosmawaiti Mohamed, Khin Maung Win, Shiv Kumar Sari declare that they have no conflict of interest.

Free to read: This content has been made available to all.